Dragonfly gets Merck on second TriNKET candidate since 2018 collab
Updated: Aug 30, 2022
Dragonfly Therapeutics is doing better and better in getting Big Pharma on its TriNKET platform. First Celgene, then BMS, and now Merck — again.
After Merck licensed its first candidate from the platform back in November 2020, the pharma giant is back for seconds as part of a 2018 collaboration between the two companies, which was initially focused on a number of solid tumor targets.
The companies expanded their collaboration last year with an agreement to develop and commercialize NK cell engaging immunotherapies for multiple targets in oncology, infectious diseases and immune disorders.
“We are delighted that Merck has now exercised its option for this second immunotherapy candidate from our initial collaboration, and excited by the progress we are making together on bringing Dragonfly’s TriNKET technology to targets across a broader set of diseases,” said Dragonfly’s CEO Bill Haney.
Merck exercised its option to license exclusive worldwide intellectual property rights on its second immunotherapy candidate developed using the TriNKET platform, under a pre-existing agreement. As for Dragonfly, it received an payment from Merck at an undisclosed amount.
It's fascinating to see how Dragonfly Therapeutics continues to strengthen its partnerships with major players like Merck. The advancements in NK cell engaging immunotherapies hold great promise for various diseases. I spent a while exploring the potential of aloha slots bonuses, and I appreciate how innovative approaches in biotechnology can parallel the creativity found in other fields. Looking forward to seeing how this collaboration evolves!
Interesting read — it’s always impressive to see partnerships and developments like this unfold in such a strategic way. The progression and context were clearly explained. I recently came across a related discussion on a review blog https://www.gourmetgiftbasketstore.com/, and it added another thoughtful angle to the topic.
Exciting news for Dragonfly and Merck! Another TriNKET candidate shows promising innovation. If you need to clean up images for presentations about this, a quick watermark remove tool might be helpful.